|
시장보고서
상품코드
2054806
가다실 시장 : 백신 유형별, 예방 대상 질환별, 투여 스케줄별, 성별, 연령층별, 최종사용자별, 유통 채널별, 지역별Gardasil Market, By Vaccine Type (Gardasil and Gardasil 9 ), By Disease Prevention Indication, By Dosage Schedule, By Gender, By Age Group (Adolescents, Young adults, and Adults ), By End User, By Distribution Channel, By Geography |
||||||
가다실 시장은 2026년에 57억 5,000만 달러로 추정되고 있으며, 2033년까지 126억 4,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 11.9%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 57억 5,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 11.90% | 2033년 시장 규모 예측 : | 126억 4,000만 달러 |
전 세계 가다실 시장은 헬스케어 및 백신 업계의 중요한 부문으로, 예방 접종을 통한 인유두종바이러스(HPV) 예방에 중점을 두고 있습니다. 머크 앤드 컴퍼니가 개발한 가다실은 자궁경부암, 생식기 사마귀 및 기타 HPV 관련 악성 종양의 주요 원인이 되는 특정 HPV 균주로부터 몸을 보호하기 위해 고안된 예방 백신입니다. 이 백신은 당초 HPV 6형, 11형, 16형, 18형을 대상으로 한 4가 백신(가다실 4)에서, 9가지 HPV 균주에 대한 예방 효과를 제공하는 현재의 9가 백신(가다실 9)으로 발전하여 예방 범위를 대폭 확대했습니다.
이 시장에는 제약 회사, 의료 서비스 제공자, 정부 보건 기관 및 다양한 연령대의 최종사용자를 포함한 다양한 이해관계자가 참여하고 있습니다. 세계보건기구(WHO)와 미국 질병통제예방센터(CDC)를 비롯한 국제 보건 기구들은 HPV 백신을 중요한 공중보건 대책으로 권장하고 있으며, 이는 선진국 및 신흥 시장에서 HPV 백신의 광범위한 보급을 촉진하고 있습니다. 시장 역학은 HPV 관련 질환에 대한 의식의 향상, 예방접종 프로그램 확대, 더 폭넓은 연령층과 성별을 대상으로 한 규제 당국의 승인, 그리고 전 세계 의료 인프라에 대한 투자 확대와 같은 요인의 영향을 받고 있으며, 가다실은 포괄적인 암 예방 전략의 필수적인 요소로서 입지를 확고히 하고 있습니다.
시장 역학
전 세계 가다실 시장은 주로 HPV 관련 암에 대한 인식이 높아지고 있는 점과, 질병 부담, 특히 전 세계 여성에게서 네 번째로 많이 발생하는 암인 자궁경부암의 부담을 줄이는 데 예방접종이 수행하는 중요한 역할에 힘입어 성장하고 있습니다. 선진국의 정부 정책과 국가 예방접종 프로그램은 시장 확산을 크게 가속화하고 있으며, 많은 국가에서 사춘기 청소년을 대상으로 한 정기 예방접종 일정에 HPV 백신 접종이 포함되어 있습니다. 초기 타깃이었던 여성층에서 남성층으로 대상 인구가 확대됨에 따라 잠재 시장이 크게 확대되었습니다. 이는 보건 당국이 집단 면역 달성 및 HPV 감염의 전반적인 감소에 있으며,성 중립적인 백신 접종 전략의 중요성을 인식하고 있기 때문입니다. 백신 제제의 기술적 진보, 특히 4가 가다실(Gardasil)에서 9가 가다실로 전환됨에 따라 예방 범위가 확대되고 시장내 입지가 강화되었습니다.
그러나 시장 억제요인으로는 가격에 민감한 지역의 접근성을 제한하는 높은 백신 비용, 특히 성병에 관한 논의가 여전히 금기시되는 보수적인 사회에서 백신 접종의 수용에 영향을 미치는 문화적·종교적 장벽 등 상당한 제약이 존재합니다. 공급망의 복잡성과 냉장 보관 요건 역시, 특히 의료 인프라가 부족한 개발도상국에서 더 큰 과제로 대두되고 있습니다. 또한 백신에 대한 반감이나 잘못된 정보의 확산으로 인해 특정 인구 집단 사이에서 접종을 주저하는 현상이 나타나고 있으며, 이는 접종률에 영향을 미치고 있습니다. 그럼에도 불구하고 의료비 증가, 인식 제고 캠페인의 확대, 의료 인프라 확충이 진행되고 있는 신흥 시장에는 막대한 성장 잠재력을 지닌 큰 기회가 존재합니다. 합리적인 가격의 백신 보급 프로그램을 위한 제약 회사와 국제 보건 기구 간의 전략적 제휴는 대상 연령층 확대 및 치료 용도로의 적용을 위한 지속적인 임상 연구와 더불어, 시장 확대와 전 세계 보건 성과 향상을 위한 유망한 길을 제시하고 있습니다.
본 조사의 주요 특징
- 본 조사에서는 다양한 부문의 잠재적 매출 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 제약 요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하는 경쟁 전략에 관한 중요 인사이트를 제공합니다.
- 본 조사에서는 다음의 파라미터(기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적, 전략)를 바탕으로 전 세계 가다실 시장의 주요 기업 개요을 작성했습니다.
- 이 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 관해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 가다실 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 가다실 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 수월하게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 가다실 시장 : 백신 유형별, 2021-2033년
제5장 세계의 가다실 시장 : 질병 예방 적응증별, 2021-2033년
제6장 세계의 가다실 시장 : 투여 스케줄별, 2021-2033년
제7장 세계의 가다실 시장 : 성별, 2021-2033년
제8장 세계의 가다실 시장 : 연령층별, 2021-2033년
제9장 세계의 가다실 시장 : 최종사용자별, 2021-2033년
제10장 세계의 가다실 시장 : 유통 채널별, 2021-2033년
제11장 세계의 가다실 시장 : 지역별, 2021-2033년
제12장 경쟁 구도
제13장 애널리스트의 제안
제14장 참고 문헌 및 조사 방법
KSA 26.06.17Gardasil Market is estimated to be valued at USD 5.75 Bn in 2026 and is expected to reach USD 12.64 Bn by 2033, growing at a compound annual growth rate (CAGR) of 11.9% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 5.75 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 11.90% | 2033 Value Projection: | USD 12.64 Bn |
The global Gardasil market represents a critical segment within the preventive healthcare and vaccine industry, focusing on human papillomavirus (HPV) prevention through immunization. Gardasil, developed by Merck & Co., is a prophylactic vaccine designed to protect against specific strains of HPV that are primarily responsible for cervical cancer, genital warts, and other HPV-related malignancies. The vaccine has evolved from its original quadrivalent formulation (Gardasil 4) targeting HPV types 6, 11, 16, and 18, to the current nonavalent version (Gardasil 9) that provides protection against nine HPV strains, significantly expanding its preventive capabilities.
The market encompasses various stakeholders including pharmaceutical manufacturers, healthcare providers, government health agencies, and end-users across different age demographics. Global health organizations, including the World Health Organization and Centers for Disease Control and Prevention, have endorsed HPV vaccination as a crucial public health intervention, driving widespread adoption across developed and emerging markets. The market dynamics are influenced by factors such as increasing awareness of HPV-related diseases, expanding vaccination programs, regulatory approvals for broader age groups and gender inclusion, and growing healthcare infrastructure investments worldwide, positioning Gardasil as an essential component of comprehensive cancer prevention strategies.
Market Dynamics
The global Gardasil market is primarily driven by escalating awareness regarding HPV-related cancers and the critical role of preventive vaccination in reducing disease burden, particularly cervical cancer which represents the fourth most common cancer among women worldwide. Government initiatives and national immunization programs across developed countries have significantly accelerated market adoption, with many nations including HPV vaccination in their routine immunization schedules for adolescents. The expansion of target demographics beyond the initial female population to include males has substantially broadened the addressable market, as healthcare authorities recognize the importance of gender-neutral vaccination strategies in achieving herd immunity and reducing overall HPV transmission. Technological advancements in vaccine formulation, particularly the transition from quadrivalent to nonavalent Gardasil, have enhanced protection coverage and improved market positioning.
However, the market faces considerable restraints including high vaccine costs that limit accessibility in price-sensitive regions, cultural and religious barriers affecting vaccination acceptance, particularly in conservative societies where discussions about sexually transmitted infections remain taboo. Supply chain complexities and cold storage requirements pose additional challenges, especially in developing countries with inadequate healthcare infrastructure. Anti-vaccine sentiment and misinformation campaigns have also created hesitancy among certain population segments, impacting uptake rates. Nevertheless, substantial opportunities exist in emerging markets where increasing healthcare spending, growing awareness campaigns, and expanding healthcare infrastructure present significant growth potential. Strategic partnerships between pharmaceutical companies and international health organizations for affordable vaccine distribution programs, coupled with ongoing clinical research for expanded age group approvals and potential therapeutic applications, represent promising avenues for market expansion and improved global health outcomes.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Gardasil market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Merck & Co. Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global Gardasil market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Gardasil market
Market Segmentation
- Vaccine Type Insights (Revenue, USD Bn, 2021 - 2033)
- Gardasil (Quadrivalent)
- Gardasil 9 (Nonavalent)
- Disease Prevention Indication Insights (Revenue, USD Bn, 2021 - 2033)
- Cervical Cancer Prevention
- Vulvar and Vaginal Cancer Prevention
- Anal Cancer Prevention
- Oropharyngeal Cancer Prevention
- Genital Warts Prevention
- Dosage Schedule Insights (Revenue, USD Bn, 2021 - 2033)
- 2-Dose Schedule
- 3-Dose Schedule
- Gender Insights (Revenue, USD Bn, 2021 - 2033)
- Male
- Female
- Age Group Insights (Revenue, USD Bn, 2021 - 2033)
- Adolescents (typically 9-14 years)
- Young adults (15-26 years)
- Adults (above 26 years)
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals and Multispecialty Centers
- Pediatric and Gynecology Clinics
- Academic and Research Institutions
- Corporate, Workplace Vaccination Programs
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Public sector
- Private sector
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Merck & Co., Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Gardasil Market, By Vaccine Type
- Global Gardasil Market, By Disease Prevention Indication
- Global Gardasil Market, By Dosage Schedule
- Global Gardasil Market, By Gender
- Global Gardasil Market, By Age Group
- Global Gardasil Market, By End User
- Global Gardasil Market, By Distribution Channel
- Global Gardasil Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Gardasil Market, By Vaccine Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Gardasil (Quadrivalent)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Gardasil 9 (Nonavalent)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Gardasil Market, By Disease Prevention Indication, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Cervical Cancer Prevention
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Vulvar and Vaginal Cancer Prevention
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Anal Cancer Prevention
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Oropharyngeal Cancer Prevention
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Genital Warts Prevention
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Gardasil Market, By Dosage Schedule, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- 2-Dose Schedule
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- 3-Dose Schedule
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Gardasil Market, By Gender, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Gardasil Market, By Age Group, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Adolescents (typically 9-14 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Young adults (15-26 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Adults (above 26 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Gardasil Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals and Multispecialty Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Pediatric and Gynecology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Academic and Research Institutions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Corporate, Workplace Vaccination Programs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global Gardasil Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Public sector
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Private sector
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
11. Global Gardasil Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Prevention Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Schedule, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Prevention Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Schedule, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Prevention Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Schedule, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Prevention Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Schedule, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Prevention Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Schedule, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Prevention Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Schedule, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
